A Phase 2 interventional study of Pactimibe in Atherosclerosis, sponsored by Sankyo Pharma Gmbh. Completed at 1 site in Germany. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2007-03-28.
Sponsored by Sankyo Pharma Gmbh · Phase 2, Interventional, and Treatment
The effect of pactimibe on the reduction of atherosclerosis in the carotid artery will be assessed using carotid ultrasound
1,567 studies on the registry are indexed under Atherosclerosis; 264 are open to participants now.
This study's enrollment of 200 is above the median of 106 across 882 interventional studies indexed under Atherosclerosis.
Browse Atherosclerosis studies →Sankyo Pharma Gmbh is the lead sponsor of 9 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Efficacy of pactimibe versus placebo on the progression of atherosclerosis
Safety and tolerability of pactimibe versus placebo in patients with atherosclerosis
This study is completed, as verified in Mar 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sankyo Pharma Gmbh